Shots:

• The approval is based on studies evaluating the safety & efficacy of Shingrix in adults aged ≥18yrs. who had undergone auHSCT and those undergoing treatment for hematological malignancies (post-hoc analysis)
• The safety & immunogenicity data were generated in adults who were or anticipated to be- immunodeficient/immunosuppressed due to known therapy including patients with HIV- solid tumors- and renal transplants
• Shingrix (IM- 2 doses) is a non-live- recombinant sub-unit adjuvanted vaccine- initially approved for the prevention of shingles in adults aged ≥50yrs. in the US. The approval for this new population expands the number of people who can be protected against shingles

 ­ Ref: GSK | Image: GSK